New schizophrenia drug passes early safety check

NCT ID NCT05406440

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called MK-8189 (elpipodect) in 53 adults with schizophrenia or schizoaffective disorder. The main goal was to see if the drug is safe and tolerable when given in increasing doses. Researchers monitored side effects and how many people stopped treatment due to problems. This is a first step to see if the drug might help control symptoms in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • California Clinical Trials Medical Group managed by PAREXEL ( Site 0002)

    Glendale, California, 91206, United States

  • Collaborative Neuroscience Research, LLC ( Site 0004)

    Garden Grove, California, 92845, United States

  • Hassman Research Institute Marlton Site ( Site 0003)

    Marlton, New Jersey, 08053, United States